Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Century Therapeutics Inc (IPSC)

Century Therapeutics Inc (IPSC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 186,173
  • Shares Outstanding, K 87,405
  • Annual Sales, $ 6,590 K
  • Annual Income, $ -126,570 K
  • EBIT $ -28 M
  • EBITDA $ -20 M
  • 60-Month Beta 1.75
  • Price/Sales 1.66
  • Price/Cash Flow N/A
  • Price/Book 0.99

Options Overview Details

View History
  • Implied Volatility 218.44% (+1.13%)
  • Historical Volatility 117.30%
  • IV Percentile 26%
  • IV Rank 15.04%
  • IV High 1,423.73% on 07/17/25
  • IV Low 5.12% on 02/17/26
  • Expected Move (DTE 23) 0.26 (11.70%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 96
  • Volume Avg (30-Day) 91
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 2,690
  • Open Int (30-Day) 3,118
  • Expected Range 1.93 to 2.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.29
  • Number of Estimates 3
  • High Estimate -0.24
  • Low Estimate -0.39
  • Prior Year -0.43
  • Growth Rate Est. (year over year) +32.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.65 +32.12%
on 02/06/26
2.71 -19.56%
on 01/27/26
-0.24 (-9.92%)
since 01/23/26
3-Month
0.50 +335.04%
on 12/03/25
2.71 -19.56%
on 01/27/26
+1.65 (+309.77%)
since 11/25/25
52-Week
0.34 +537.80%
on 04/09/25
2.71 -19.56%
on 01/27/26
+1.48 (+210.54%)
since 02/25/25

Most Recent Stories

More News
Century Therapeutics to Participate in Upcoming Investor Conferences in March

PHILADELPHIA, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies...

IPSC : 2.18 (+2.35%)
Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes

PHILADELPHIA, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies...

IPSC : 2.18 (+2.35%)
Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors

PHILADELPHIA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies...

IPSC : 2.18 (+2.35%)
Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference

PHILADELPHIA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies...

IPSC : 2.18 (+2.35%)
Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Announced iPSC derived beta islet cell program for Type 1 diabetes (T1D); Investigational New Drug (IND)-enabling studies expected to initiate by year-end 2025; IND submission planned in 2026 CNTY-308...

IPSC : 2.18 (+2.35%)
Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes

Allo-Evasion™ 5.0-engineered iPSC beta islets are designed to overcome immune rejection and provide durable glucose control without chronic immunosuppression Compelling preclinical data demonstrate...

IPSC : 2.18 (+2.35%)
Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference

PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies...

IPSC : 2.18 (+2.35%)
Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

PHILADELPHIA, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell...

IPSC : 2.18 (+2.35%)
Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Patient dosing ongoing in CALiPSO-1 trial; on track to report clinical data for CNTY-101 in patients with B-cell-mediated autoimmune diseases by year-end 2025 CNTY-308, a CAR-iT cell therapy functionally...

IPSC : 2.18 (+2.35%)
Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress

IPSC : 2.18 (+2.35%)

Business Summary

Century Therapeutics Inc. is a cell therapy company. It involved in developing induced pluripotent stem cell -derived cell therapies in immuno-oncology. Century Therapeutics Inc. is based in PHILADELPHIA.

See More

Key Turning Points

3rd Resistance Point 2.49
2nd Resistance Point 2.42
1st Resistance Point 2.30
Last Price 2.18
1st Support Level 2.11
2nd Support Level 2.04
3rd Support Level 1.92

See More

52-Week High 2.71
Last Price 2.18
Fibonacci 61.8% 1.81
Fibonacci 50% 1.53
Fibonacci 38.2% 1.25
52-Week Low 0.34

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar